•This report describes the first use of recombinant-DNA-produced human interferon in patients with multiple sclerosis (MS). Ninety-eight patients who were clinically definite for MS with two or more documented exacerbations during the preceding two years were admitted to this placebo-controlled double-blind randomized trial. Although both groups were similar, placebo patients had later MS onset. Patients injected themselves with 2 X 106 lU of α-2interferon or placebo three times each week for up to 52 weeks. This dose of interferon was well tolerated in that side effects were minimal. During the trial, the exacerbation rate was sharply reduced in both groups. In the three-month follow-up period after stopping treatment, more patients who were receiving interferon than placebo became worse neurologically. More patients who were receiving interferon than placebo changed from exacerbating MS to progressive MS during the trial. Thus, no clear therapeutic benefit of α-2 interferon for MS was detected.
Camenga DL, Johnson, KP, Alter M, et al. Systemic Recombinant α-2Interferon Therapy in Relapsing Multiple Sclerosis. Arch Neurol. 1986;43(12):1238–1246. doi:10.1001/archneur.1986.00520120023011
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.